- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03497494
the Related Factors of Bariatric Surgery on Gastroesophageal Reflux Disease
Analysis the Related Factors of Bariatric Surgery on Gastroesophageal Reflux Disease and Its Prevention and Treatment: a Prospective, Multicenter and Randomized Controlled Study
Obesity and related metabolic diseases have become a chronic disease that is a threat to human health. Bariatric surgery can effectively and long-term reduce excess body weight and relieve related metabolic diseases, including type 2 diabetes. Laparoscopic gastric bypass surgery and laparoscopic sleeve gastrectomy are commonly used in bariatric surgery. Laparoscopic sleeve gastrectomy due to simple operation, good weight loss, and metabolic disease control effect, which is more widely used. However, there are several studies that show an increased chance of gastroesophageal reflux disease after laparoscopic sleeve gastrectomy. Long-term gastroesophageal reflux may lead to Barrett's esophagus or esophageal cancer. Nowadays, the cause of gastroesophageal reflux disease after sleeve gastrectomy is not clear and precautionary measures are not precise.
In this study, prospective randomized controlled trials were conducted to explore the possible causes of gastroesophageal reflux after sleeve gastrectomy and to explore ways to prevent gastroesophageal reflux disease after sleeve gastrectomy.
Přehled studie
Postavení
Detailní popis
With the social development and changes in the lifestyle, the incidence of obesity and type 2diabetes is rapidly increasing. In 2010, the global incidence of type 2 diabetes was 8.3% in adults, 11.6% in China and 50.1% in China. In overweight and obese people, the prevalence of type 2 diabetes also increased significantly, and the prevalence of type 2diabetes in those people with BMI> 30 reached 18.5-23%. Diabetes-induced cardiovascular and cerebrovascular diseases, renal insufficiency and other complications, seriously affecting the quality of life of the patients, endangering the safety of life, the treatment of type 2 diabetes and related complications to public health expenditure has brought tremendous pressure.
Traditional medical methods are difficult to achieve long-term and effective control of type 2 diabetes. Surgery has been shown to achieve 75-95% long-term relief of obesity in patients. Roux-en-Y gastric bypass (Roux-en-Y gastric bypass, RYGB) and laparoscopic sleeve gastrectomy are most commonly used. Among them, laparoscopic sleeve gastrectomy is relatively simple, low incidence of complications, lower operating costs, and gradually become the most important surgical methods of weight loss and metabolic disease surgery. Numerous clinical studies are shown that sleeve gastrectomy in patients with type 2 diabetes has the same therapeutic effect as gastric bypass with a complete remission rate of 70-90% for T2DM.
For the choice of surgical approach, numerous studies have shown that BMI ≧ 45, the general choice of gastric bypass surgery, BMI <45, participants can choose sleeve gastrectomy. The remission rate for T2DM, sleeve gastrectomy has a good result for young patients with shorter duration. In China, the BMI less than 45 is majorities.
According to the previous survey in 2012, the newly diagnosed diabetes patients in China constituted more than half of all diabetic patients. Since laparoscopic sleeve gastrectomy is relatively simple, so sleeve gastrectomy is easier to popularize in China and has wide application prospect.
As an invasive treatment, laparoscopic sleeve gastrectomy also presents opportunities of surgery-related complications, including gastric leak (0.5-1%), stenosis (0.1-0.5%), bleeding (about 0.5%), and gastroesophageal reflux disease (GERD). Gastroesophageal reflux disease is a most common upper gastrointestinal disease, numerous clinical studies shown that the incidence of GERD in western populations are 10-20%, while obese people are around 37-72%, if abdominal fat accumulation more obvious, the incidence of GERD will become higher. In China, there is still no relevant data. Gastric bypass surgery has a clear effect on the treatment of GERD, and the relationship between sleeve gastrectomy and GERD is still controversial. Some studies have shown that sleeve gastrectomy did not increase the incidence of postoperative GERD, while another study showed that the incidence of GERD after sleeve gastrectomy increased significantly. In addition, no studies have revealed the reasons for the occurrence of GERD after sleeve gastrectomy and no study showed how to prevent the occurrence of GERD after sleeve gastrectomy.
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Guangdong
-
Guangzhou, Guangdong, Čína, 510630
- The frist affiliated hospital of Jinan University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- For the choice of surgical approach, numerous studies have shown that BMI ≧ 45, the general choice of gastric bypass surgery, BMI <45, you can choose sleeve gastrectomy. The remission rate for T2DM, sleeve gastrectomy has a good result for young patients with shorter duration. In our country, the BMI less than 45 is majorities.
Exclusion Criteria:
- BMI<27.5
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Trojnásobný
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Without hiatal suture
the different distance of pylorus without hiatal suture
|
2 cm away from the pylorus edge
4 cm away from the pylorus edge
6 cm away from the pylorus edge
laparoscopic Roux-en-Y gastric bypass
Ostatní jména:
|
|
Aktivní komparátor: With hiatal suture
the different distance of pylorus without hiatal suture
|
2 cm away from the pylorus edge
4 cm away from the pylorus edge
6 cm away from the pylorus edge
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
GERD-Health Related Quality of Life Questionnaire
Časové okno: 1 year
|
Total Score: Calculated by summing the individual scores to questions 1-15.
|
1 year
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
preoperative and postoperative of abdominal ultrasound to examine the abdominal fat thickness
Časové okno: 1 year
|
abdominal fat thickness in centimeter
|
1 year
|
|
Preoperative and postoperative BMI
Časové okno: 1 year
|
The patient's weight and height will be combined to report BMI in kg/m^2
|
1 year
|
|
Preoperative and postoperative waist circumference
Časové okno: 1 year
|
waist circumference in centimeter
|
1 year
|
|
Preoperative and postoperative abdominal circumference
Časové okno: 1 year
|
abdominal circumference in centimeter
|
1 year
|
|
Preoperative and postoperative chest circumference
Časové okno: 1 year
|
chest circumference in centimeter
|
1 year
|
|
Preoperative and postoperative neck circumference
Časové okno: 1 year
|
neck circumference in centimeter
|
1 year
|
|
Preoperative and postoperative bone mineral density
Časové okno: 1 year
|
bone mineral density in percentage
|
1 year
|
|
Preoperative and postoperative body fat measured
Časové okno: 1 year
|
body fat measured in percentage
|
1 year
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- FirstJinanU20180120
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Gastroezofageální reflux
-
Cleveland Clinic LondonZápis na pozvánkuLaryngofaryngeální reflux | Gastro -eozofagální refluxSpojené arabské emiráty, Rakousko, Itálie, Srbsko, Švýcarsko, Turecko (Türkiye), Spojené království
-
Medical University of ViennaNeznámý
-
Shandong UniversityZatím nenabírámeUmělá inteligence | Reflux žluči | JazykČína
-
University Hospital MuensterDokončenoReflux, Gastroezofageální | Refluxní nemoc | Reflux, LaryngofaryngeálníNěmecko
-
Samsung Medical CenterDokončenoVezikoureterální refluxKorejská republika
-
Vanderbilt University Medical CenterAmenity Health, Inc.Ukončeno
-
St. Luke's Medical Center, PhilippinesDokončenoInfekce močových cest | Vezikoureterální reflux (VUR)Filipíny
-
Stanford UniversityDokončenoVezikoureterální refluxSpojené státy
-
Aplos MedicalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Aktivní, ne nábor
-
Medtronic EndovascularVNUS Medical Technologies, A Covidien CompanyDokončeno